Transfer of brotizolam, periciazine, and sulpiride in cord blood and breast milk, and alprazolam in breast milk: a case report

Jumpei Saito, Yoshiyuki Tachibana, Yuka Sano Wada, Naho Yakuwa, Hiroyo Kawasaki, Tomo Suzuki, Haruhiko Sago, Akimasa Yamatani, Atsuko Murashima, Jumpei Saito, Yoshiyuki Tachibana, Yuka Sano Wada, Naho Yakuwa, Hiroyo Kawasaki, Tomo Suzuki, Haruhiko Sago, Akimasa Yamatani, Atsuko Murashima

Abstract

Background: A high prevalence of mental disorders including depression, anxiety, somatoform, and dissociative disorder is reported during pregnancy, however, information on the transfer of antipsychotics across the placenta and into breast milk is limited. We evaluated brotizolam, periciazine and sulpiride in cord blood, maternal serum, and breast milk, and alprazolam in breast milk.

Case presentation: A 38-year-old woman with dissociative disorder was treated with brotizolam, propericiazine, and sulpiride during pregnancy and lactation, and alprazolam during lactation. The drug concentration ratios for both cord blood and maternal serum were 33.3 and 61.5% for brotizolam and sulpiride, respectively, and periciazine (metabolite of propericiazine) was not detected in the cord blood. In breast milk, alprazolam (0.9 ng/mL), sulpiride (445.8 ng/mL), and periciazine (0.3 ng/mL) concentrations were noted at 7.5 h after the last dose on postpartum, whereas brotizolam was not detected. The relative infant doses via breast milk were 1.4, 2.7 and 0.02% of the maternal daily dose, respectively. The neonate had no congenital anomalies and did not experience any severe withdrawal symptoms after birth.

Conclusion: Use of brotizolam, propericiazine, and sulpiride during pregnancy and lactation, and use of alprazolam during lactation were acceptable in this case.

Keywords: Lactation; Pregnancy; Psychiatry; Psychotherapy.

Conflict of interest statement

A Murashima received research grant and lecture fee from Chugai Pharmaceutical, Co., Ltd. All other authors declare no conflicts of interest. Each author has confirmed compliance with the journal’s requirements for authorship.

© 2022. The Author(s).

References

    1. Wallwiener S, Goetz M, Lanfer A, Gillessen A, Suling M, Feisst M, et al. Epidemiology of mental disorders during pregnancy and link to birth outcome: a large-scale retrospective observational database study including 38,000 pregnancies. Arch Gynecol Obstet. 2019;299:755–763. doi: 10.1007/s00404-019-05075-2.
    1. Lacroix I, Hurault C, Sarramon MF, Guitard C, Berrebi A, Grau M, et al. Prescription of drugs during pregnancy: a study using EFEMERIS, the new French database. Eur J Clin Pharmacol. 2009;65:839–846. doi: 10.1007/s00228-009-0647-2.
    1. Hanley GE, Mintzes B. Patterns of psychotropic medicine use in pregnancy in the United States from 2006 to 2011 among women with private insurance. BMC Pregnancy Childbirth. 2014;14:242. doi: 10.1186/1471-2393-14-242.
    1. Aliaga A, Cunillera O, Amador MDC, Aliaga M, Arquerons M, Almeda J. Association between affective disorders presenting before and during pregnancy and pre-term birth, considering socio-demographic factors, obstetric factors, health conditions, and use of medication. Aten Primaria. 2019;51:626–636. doi: 10.1016/j.aprim.2018.06.009.
    1. Calderon-Margalit R, Qiu C, Ornoy A, Siscovick DS, Williams MA. Risk of preterm delivery and other adverse perinatal outcomes in relation to maternal use of psychotropic medications during pregnancy. Am J Obstet Gynecol. 2009;201:579.e1–579.e5798. doi: 10.1016/j.ajog.2009.06.061.
    1. Einarson A, McKenna K, Levinson A. Review: women with schizophrenia have poorer pregnancy outcomes than other women, but it is unclear whether antipsychotic medications affect their infants. Evid Based Ment Health. 2003;6:89. doi: 10.1136/ebmh.6.3.89.
    1. Convertino I, Sansone AC, Marino A, Galiulo MT, Mantarro S, Antonioli L, et al. Neonatal adaptation issues after maternal exposure to prescription drugs: withdrawal syndromes and residual pharmacological effects. Drug Saf. 2016;39:903–924. doi: 10.1007/s40264-016-0435-8.
    1. Isobe K, Ishii M, Kusaka T. Research on systemic care system for a high risk child management of newborn babies with the withdrawal syndrome. Questionnaire survey on evaluation method by a check list and score table. 1995. . Accessed 20 Mar 2022.
    1. Aono T, Shioji T, Aki T, Hirota K, Nomura A, Kurachi K. Augmentation of puerperal lactation by oral administration of sulpiride. J Clin Endocrinol Metab. 1979;48:478–482. doi: 10.1210/jcem-48-3-478.
    1. Saito J, Ishii M, Miura Y, Yakuwa N, Kawasaki H, Suzuki T, et al. Brotizolam during pregnancy and lactation: Brotizolam levels in maternal serum, cord blood, breast milk, and neonatal serum. Breastfeed Med. 2021;16:579–582. doi: 10.1089/bfm.2021.0013.
    1. Iqbal MM, Sobhan T, Ryals T. Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. Psychiatr Serv. 2002;53:39–49. doi: 10.1176/appi.ps.53.1.39.
    1. Bai M, Ma Z, Sun D, Zheng C, Weng Y, Yang X, et al. Multiple drug transporters mediate the placental transport of sulpiride. Arch Toxicol. 2017;91:3873–3884. doi: 10.1007/s00204-017-2008-8.
    1. Oo CY, Kuhn RJ, Desai N, Wright CE, McNamara PJ. Pharmacokinetics in lactating women: prediction of alprazolam transfer into milk. Br J Clin Pharmacol. 1995;40:231–236. doi: 10.1111/j.1365-2125.1995.tb05778.x.
    1. Furugen A, Nishimura A, Kobayashi M, Umazume T, Narumi K, Iseki K. Quantification of eight benzodiazepines in human breastmilk and plasma by liquid-liquid extraction and liquid-chromatography tandem mass spectrometry: application to evaluation of alprazolam transfer into breastmilk. J Pharm Biomed Anal. 2019;168:83–93. doi: 10.1016/j.jpba.2019.02.011.
    1. Nishimura A, Furugen A, Umazume T, Kitamura S, Soma M, Noshiro K, et al. Benzodiazepine concentrations in the breast milk and plasma of nursing mothers: estimation of relative infant dose. Breastfeed Med. 2021;16:424–431. doi: 10.1089/bfm.2020.0259.
    1. Ylikorkala O, Kauppila A, Kivinen S, Viinikka L. Sulpiride improves inadequate lactation. Br Med J (Clin Res Ed) 1982;285:249–251. doi: 10.1136/bmj.285.6337.249.
    1. Ylikorkala O, Kauppila A, Kivinen S, Viinikka L. Treatment of inadequate lactation with oral sulpiride and buccal oxytocin. Obstet Gynecol. 1984;63:57–60.
    1. SJ OH, Wong A, Joyce DA. A liquid chromatography-tandem mass spectrometry method for quantifying amisulpride in human plasma and breast milk, applied to measuring drug transfer to a fully breast-fed neonate. Ther Drug Monit. 2016;38:493–498. doi: 10.1097/FTD.0000000000000300.
    1. Kanemura A, Masamoto H, Kinjo T, Mekaru K, Yoshida T, Goya H, et al. Evaluation of neonatal withdrawal syndrome in neonates delivered by women taking psychotropic or anticonvulsant drugs: A retrospective chart review of the effects of multiple medications and breastfeeding. Eur J Obstet Gynecol Reprod Biol. 2020;254:226–230. doi: 10.1016/j.ejogrb.2020.09.008.
    1. Shyken JM, Babbar S, Babbar S, Forinash A. Benzodiazepines in Pregnancy. Clin Obstet Gynecol. 2019;62:156–167. doi: 10.1097/GRF.0000000000000417.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する